# US 12,006,342 B2 · Proteins and nucleic acids useful in vaccines targeting Pseudomonas aeruginosa

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,006,342 B2
- Document ID: US12006342B2
- Status: Granted
- Kind: B2
- Application number: 17/532,034
- Filed: 2021-11-22
- Published: 2022-03-10
- Granted: 2024-06-11
- Earliest claimed: 2015-07-04
- Assignees: Evaxion Biotech A/S
- Applicants: Evaxion Biotech A/S
- Inventors: Niels Iversen Møller; Andreas Holm Mattsson
- Web page: https://patentgrep.com/patent/US12006342B2

## CPC

- C07K 14/21: from Pseudomonadaceae (F)
- A61K 39/104: {Pseudomonadales, e.g.} Pseudomonas
- A61K 47/6415: {Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins}
- A61K 47/643: {Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]}
- A61K 47/646: {the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines}
- A61P 31/04: Antibacterial agents
- C07K 16/1214: Pseudomonadaceae (F)
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K 2039/55505: {Inorganic adjuvants}
- A61K 2039/575: {humoral response}
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Disclosed are immunogenic proteins from Pseudomonas aeruginosa as well as nucleic acids, vectors and transformed cells useful for expression of the proteins. Also disclosed are methods for prophylaxis of infection with Pseudomonas aeruginosa using the proteins, nucleic acids, vectors or transformed cells.

## Claims

### Claim 1

A pharmaceutical composition comprising a polypeptide and a pharmaceutically acceptable carrier, vehicle or diluent, and an immunological adjuvant,
wherein the polypeptide comprises:
a) an amino acid sequence consisting of residues 29-742 of SEQ ID NO: 18, or
b) an amino acid sequence consisting of at least or exactly 100 contiguous amino acids from residues 29-742 of SEQ ID NO: 18, or
c) an amino acid sequence having a sequence identity of at least 90% with the amino acid sequence of a), or
d) an amino acid sequence having a sequence identity of at least 90% with the amino acid sequence of b),
wherein the polypeptide lacks amino acid residues 1-28 in SEQ ID NO: 18, and wherein the polypeptide is antigenic in a human being, to which the polypeptide has been administered.

### Claim 2 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the adjuvant is an aluminium based adjuvant.

### Claim 3 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the at least 100 contiguous amino acid residues have an N-terminal amino acid residue corresponding to any one of amino acid residues 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382, 383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410, 411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438, 439, 440, 441, 442, 443, 444, 445, 446, 447, 448, 449, 450, 451, 452, 453, 454, 455, 456, 457, 458, 459, 460, 461, 462, 463, 464, 465, 466, 467, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479, 480, 481, 482, 483, 484, 485, 486, 487, 488, 489, 490, 491, 492, 493, 494, 495, 496, 497, 498, 499, 500, 501, 502, 503, 504, 505, 506, 507, 508, 509, 510, 511, 512, 513, 514, 515, 516, 517, 518, 519, 520, 521, 522, 523, 524, 525, 526, 527, 528, 529, 530, 531, 532, 533, 534, 535, 536, 537, 538, 539, 540, 541, 542, 543, 544, 545, 546, 547, 548, 549, 550, 551, 552, 553, 554, 555, 556, 557, 558, 559, 560, 561, 562, 563, 564, 565, 566, 567, 568, 569, 570, 571, 572, 573, 574, 575, 576, 577, 578, 579, 580, 581, 582, 583, 584, 585, 586, 587, 588, 589, 590, 591, 592, 593, 594, 595, 596, 597, 598, 599, 600, 601, 602, 603, 604, 605, 606, 607, 608, 609, 610, 611, 612, 613, 614, 615, 616, 617, 618, 619, 620, 621, 622, 623, 624, 625, 626, 627, 628, 629, 630, 631, 632, 633, 634, 635, 636, 637, 638, 639, 640, 641, 642, and 643 in SEQ ID NO; 18 with the proviso that the selected amino acid residue satisfies the formula N≤743−n, where N is the number of the selected residue, and n is the number of consecutive amino acid residues.

### Claim 4 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the polypeptide comprises under c) or d) an amino acid sequence having a sequence identify of 95% with the amino acid sequence of a) or b), respectively.

### Claim 5 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the polypeptide is fused or conjugated to an immunogenic carrier molecule.

### Claim 6 (depends on 5)

The pharmaceutical composition according to claim 5, wherein the immunogenic carrier molecule is a polypeptide that induces T-helper lymphocyte responses in a majority of humans, such as immunogenic carrier proteins selected from the group consisting of keyhole limpet hemocyanin or a fragment thereof, tetanus toxoid or a fragment thereof, diphtheria toxoid or a fragment thereof.

### Claim 7 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the polypeptide comprises an amino acid sequence consisting of at least or exactly 200 contiguous amino acid residues from residues 29-742 of SEQ ID NO: 18.

### Claim 8 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the polypeptide comprises an amino acid sequence consisting of at least or exactly 290 contiguous amino acid residues from residues 29-742 of SEQ ID NO: 18.

### Claim 9 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the polypeptide comprises an amino acid sequence consisting of at least or exactly 400 contiguous amino acid residues from residues 29-742 of SEQ ID NO: 18.

### Claim 10 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the polypeptide comprises an amino acid sequence consisting of at least or exactly 500 contiguous amino acid residues from residues 29-742 of SEQ ID NO: 18.

### Claim 11 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the polypeptide comprises an amino acid sequence consisting of at least or exactly 600 contiguous amino acid residues from residues 29-742 of SEQ ID NO: 18.

### Claim 12 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the polypeptide comprises an amino acid sequence consisting of at least or exactly 700 contiguous amino acid residues from residues 29-742 of SEQ ID NO: 18.

### Claim 13 (depends on 1)

The pharmaceutical composition according to claim 1, where in the polypeptide comprises an amino acid sequence consisting of an amino acid sequence with at least 90% sequence identity with at least or exactly 200 contiguous amino acid residues from residues 29-742 of SEQ ID NO: 18.

### Claim 14 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the polypeptide comprises an amino acid sequence consisting of an amino acid sequence with at least 90% sequence identity with at least or exactly 290 contiguous amino acid residues from residues 29-742 of SEQ ID NO: 18.

### Claim 15 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the polypeptide comprises an amino acid sequence consisting of an amino acid sequence with at least 90% sequence identity with at least or exactly 400 contiguous amino acid residues from residues 29-742 of SEQ ID NO: 18.

### Claim 16 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the polypeptide comprises an amino acid sequence consisting of an amino acid sequence with at least 90% sequence identity with at least or exactly 500 contiguous amino acid residues from residues 29-742 of SEQ ID NO 18.

### Claim 17 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the polypeptide comprises an amino acid sequence consisting of an amino acid sequence with at least 90% sequence identity with at least or exactly 600 contiguous amino acid residues from residues 29-742 of SEQ ID NO 18.

### Claim 18 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the polypeptide comprises an amino acid sequence consisting of an amino acid sequence with at least 90% sequence identity with at least or exactly 700 contiguous amino acid residues from residues 29-742 of SEQ ID NO: 18.